An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index

PURPOSE: Antibody-drug conjugates (ADCs) have emerged as a potent cancer therapeutic option in recent years. DP303c is a HER2-targeting ADC with a cleavable linker-MMAE payload. The current study aimed to evaluate the therapeutic potentials of DP303c in vitro as well as in vivo. MATERIALS AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Hui, Xiwu, Yuan, Can, Cao, Weirong, Ge, Wenli, Zhang, Di, Dan, Mo, Zhao, Qian, Liu, Boning, Yao, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005139/
https://www.ncbi.nlm.nih.gov/pubmed/35422630
http://dx.doi.org/10.2147/OTT.S357326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005139/
https://www.ncbi.nlm.nih.gov/pubmed/35422630
http://dx.doi.org/10.2147/OTT.S357326

Ejemplares similares